CTLA4 and Hepatitis: The incidence of ICI-derived hepatitis is approximately 1-3% for programmed cell death 1 (PD1) inhibitors and 3-9% in cytotoxic T-lymphocyte-associated protein 4 (CTLA4) inhibitors (198).